ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate

Min Xie, Uday S. Ganapathy, Tian Lan, Paulina Osiecki, Jansy P. Sarathy, Véronique Dartois, Courtney C. Aldrich, Thomas Dick

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Necrotic lesions and cavities filled with caseum are a hallmark of mycobacterial pulmonary disease. Bronchocavitary Mycobacterium abscessus disease is associated with poor treatment outcomes. In caseum surrogate, M. abscessus entered an extended stationary phase showing tolerance to killing by most current antibiotics, suggesting that caseum persisters contribute to the poor performance of available treatments. Novel ADP-ribosylation-resistant rifabutin analogs exhibited bactericidal activity against these M. abscessus persisters at concentrations achievable by rifamycins in caseum.

Original languageEnglish (US)
JournalAntimicrobial agents and chemotherapy
Volume67
Issue number9
DOIs
StatePublished - Sep 2023

Bibliographical note

Publisher Copyright:
Copyright © 2023 Xie et al.

Keywords

  • ADP-ribosylase
  • NTM
  • caseum
  • drug tolerance
  • non-tuberculous mycobacteria
  • persistence
  • rifamycins

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug-tolerant M. abscessus in caseum surrogate'. Together they form a unique fingerprint.

Cite this